UBS Ups BrightSpring Goal to $42, Reiterated Purchase After Beat-and-Increase Q3

BrightSpring Well being Providers, Inc. (NASDAQ:BTSG) is without doubt one of the greatest digital well being shares to purchase now.

On October 29, sooner or later after the corporate’s launch of Q3 outcomes, UBS analyst A.J. Rice. reiterated Purchase and lifted their 12-month worth goal to $42 (from $35), citing a basic “beat-and-raise” quarter and administration’s confidence, particularly round specialty/infusion momentum carrying into 2026.

On October 28, BrightSpring Well being Providers, Inc. (NASDAQ:BTSG) reported income of $3.334 billion (+28.2% YoY), adjusted EBITDA of $160 million (+37.2% YoY), and internet earnings of $37.5 million versus a prior-year loss.

Photographee.eu/Shutterstock.com

The combo did the heavy lifting: Pharmacy Options grew ~31% to $2.97 billion on specialty and infusion power, whereas Supplier Providers rose ~9% to $367 million. Administration raised FY25 income steering to $12.4–$12.7 billion and saved adjusted EBITDA at $605–$615 million, pointing to continued specialty quantity, limited-distribution drug provides, and execution on the pharmacy platform.

BrightSpring Well being Providers, Inc. (NASDAQ:BTSG) is a post-acute care firm providing house and community-based medical providers, in addition to pharmacy options, throughout the USA. It serves medically advanced and growing older populations by way of a mixture of in-home care, behavioral well being help, and drugs administration.

Whereas we acknowledge the potential of BTSG as an funding, we imagine sure AI shares provide larger upside potential and carry much less draw back danger. In case you’re in search of a particularly undervalued AI inventory that additionally stands to profit considerably from Trump-era tariffs and the onshoring pattern, see our free report on the greatest short-term AI inventory. READ NEXT: 30 Shares That Ought to Double in 3 Years and 11 Hidden AI Shares to Purchase Proper Now. Disclosure: None.